Ursane-type triterpenoids, most notably ursolic acid, have been investigated for their hepatoprotective properties, including potential roles in the management or support of liver cirrhosis. Scientific studies, primarily in vitro and in animal models, have demonstrated that ursolic acid exhibits anti-inflammatory, anti-fibrotic, and antioxidant effects on liver tissue. These properties are relevant because cirrhosis involves chronic inflammation and progressive fibrosis of the liver.

Several preclinical studies have shown that ursolic acid can inhibit the activation of hepatic stellate cells, which play a central role in liver fibrosis. It has also been reported to suppress the expression of pro-fibrotic cytokines such as TGF-β1 and reduce oxidative stress markers in rodent models of chemically induced cirrhosis. Additionally, ursolic acid has been found to modulate pathways involved in apoptosis and cellular proliferation, which may further contribute to its hepatoprotective effects.

However, clinical evidence in humans is sparse. There are very few, if any, well-designed clinical trials assessing the efficacy of ursane-type triterpenoids in patients with cirrhosis. Most of the available data are preclinical, and more research is needed to confirm these findings in humans. In summary, while there is a scientific rationale and promising preclinical data, the evidence supporting the use of ursane-type triterpenoids for cirrhosis is currently limited to animal and laboratory studies.